Epizyme (EPZM) closed the latest buying and selling day at $20.93, transferring -1.83% from the earlier buying and selling session. This transfer lagged the S&P 500’s day by day lack of 1.77%. On the identical time, the Dow misplaced 2.09%, and the tech-heavy Nasdaq misplaced 1.59%.
Coming into right now, shares of the biopharmaceutical firm had misplaced 14.38% prior to now month. In that very same time, the Medical sector misplaced 1.19%, whereas the S&P 500 gained 2.04%.
Traders can be hoping for power from EPZM because it approaches its subsequent earnings launch. On that day, EPZM is projected to report earnings of -$0.51 per share, which might characterize a year-over-year decline of 75.86%. In the meantime, our newest consensus estimate is looking for income of $2.83 million, down 70.79% from the prior-year quarter.
Any latest modifications to analyst estimates for EPZM also needs to be famous by buyers. These revisions assist to point out the ever-changing nature of near-term enterprise traits. As such, optimistic estimate revisions replicate analyst optimism in regards to the firm’s enterprise and profitability.
…